Key pointsPhylogica is developing next generation intracellular biological therapeutics, including its own preclinical Myc, STAT 5 and YB1 oncology inhibitor payloads, using its proprietary best-in-class cell penetrating FPPs.
Phylogica – Key Investment Highlights• Addressing a large unmet market need - $250Bn for biologics targeting “undruggable” targets and $110Bn cancer treatment
• Derisked investment opportunity - progressing 3 asset groups - intracellular delivery, biologic therapeutic solutions and new drug discovery
• Well validated platform technology - partnerships with Genentech, MedImmune, Pfizer, Janssen Biotech and Roche
• Strong patent position - international patents in place
• Best-in-Class compounds - leading programs FPP and iMyc are better than existing gold standard solutions
• High calibre team - attracted world-class talent from the industry and commercial sector
• Blue sky potential - extensive Phylomer library ensures a high hit rate on any target of interest
